Analysts Set SAB Biotherapeutics, Inc. (NASDAQ:SABS) Price Target at $10.00

SAB Biotherapeutics, Inc. (NASDAQ:SABS) has earned a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $10.00.

Several equities research analysts recently issued reports on the stock. Weiss Ratings restated a “sell (d)” rating on shares of SAB Biotherapeutics in a report on Monday, December 29th. Chardan Capital reissued a “buy” rating and set a $12.00 price target on shares of SAB Biotherapeutics in a report on Thursday, December 18th. UBS Group initiated coverage on SAB Biotherapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $7.00 price target on the stock. Guggenheim assumed coverage on SAB Biotherapeutics in a report on Friday, December 19th. They issued a “buy” rating and a $15.00 price objective for the company. Finally, Wall Street Zen upgraded SAB Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd.

SAB Biotherapeutics Price Performance

NASDAQ SABS opened at $4.28 on Friday. SAB Biotherapeutics has a one year low of $1.00 and a one year high of $6.60. The stock has a 50-day moving average of $3.87 and a 200 day moving average of $2.97. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.50 and a current ratio of 10.49. The company has a market capitalization of $203.77 million, a price-to-earnings ratio of -1.39 and a beta of 0.58.

SAB Biotherapeutics (NASDAQ:SABS) last posted its earnings results on Thursday, November 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.38. On average, sell-side analysts forecast that SAB Biotherapeutics will post -3.69 EPS for the current year.

Hedge Funds Weigh In On SAB Biotherapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in SABS. HB Wealth Management LLC purchased a new stake in shares of SAB Biotherapeutics in the 3rd quarter worth $618,000. Vivo Capital LLC bought a new stake in SAB Biotherapeutics during the third quarter valued at about $22,954,000. RA Capital Management L.P. purchased a new stake in SAB Biotherapeutics in the third quarter worth about $8,847,000. Woodline Partners LP purchased a new stake in SAB Biotherapeutics in the third quarter worth about $5,730,000. Finally, Virtu Financial LLC bought a new position in shares of SAB Biotherapeutics in the third quarter worth about $40,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.